G
GRAIL, LLC
NASDAQ: GRAL (GRAIL, Inc.)
Last update: 6 hours ago67.87
-0.37 (-0.54%)
| Previous Close | 68.24 |
| Open | 67.98 |
| Volume | 433,177 |
| Avg. Volume (3M) | 704,648 |
| Market Cap | 3,031,497,216 |
| Price / Sales | 16.50 |
| Price / Book | 1.19 |
| 52 Weeks Range |
| Operating Margin (TTM) | -482.59% |
| Diluted EPS (TTM) | -59.59 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 9.70 |
| Operating Cash Flow (TTM) | -464.88 M |
| Levered Free Cash Flow (TTM) | -236.88 M |
| Return on Assets (TTM) | -11.98% |
| Return on Equity (TTM) | -62.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | GRAIL, Inc. | Mixed | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 66.50% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |